Search research articles
Contact Us
Filters
Showing results (61-70 of 66) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 66 results.
The Journal of Urology
|
October 23, 2012
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer
Christopher J Ricketts, Brian Shuch, Cathy D Vocke, et al.
Oncotarget
|
March 15, 2018
Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancers
Carole Sourbier, Pei-Jyun Liao, Christopher J Ricketts, et al.
Cancer Cell
|
December 10, 2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer
Carole Sourbier, Christopher J Ricketts, Shingo Matsumoto, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 24, 2023
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
Martin Lang, Laura S Schmidt, Kelli M Wilson, et al.
Science Signaling
|
January 6, 2021
Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Daniel R Crooks, Nunziata Maio, Martin Lang, et al.
Molecular Cancer Therapeutics
|
October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 66) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 66 results.
The Journal of Urology
|
October 23, 2012
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer
Christopher J Ricketts, Brian Shuch, Cathy D Vocke, et al.
Oncotarget
|
March 15, 2018
Targeting loss of the Hippo signaling pathway in <i>NF2</i>-deficient papillary kidney cancers
Carole Sourbier, Pei-Jyun Liao, Christopher J Ricketts, et al.
Cancer Cell
|
December 10, 2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer
Carole Sourbier, Christopher J Ricketts, Shingo Matsumoto, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 24, 2023
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
Martin Lang, Laura S Schmidt, Kelli M Wilson, et al.
Science Signaling
|
January 6, 2021
Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Daniel R Crooks, Nunziata Maio, Martin Lang, et al.
Molecular Cancer Therapeutics
|
October 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82
Susana S Najera, Christopher J Ricketts, Laura S Schmidt, et al.
Page
of 7